Apolipoprotein E (apoE), a 299-amino acid protein, is the primary apolipoprotein found in the central nervous system (CNS). In the brain, APOE3 polymorphism is adaptive and downregulates glial activation and secondary neuronal injury. However, APOE4 diminishes these anti-inflammatory properties and is associated with increased cerebral edema after brain injury. Due to its size, the intact apoE holoprotein does not cross the blood-brain-barrier and has limited therapeutic potential as a treatment for neurological disease. To address this limitation, the team created smaller, 5-amino acid, apoE-mimetic peptides. The lead candidate, CN-105, is moving through the drug development pipeline and is now in early Phase II trials in the US and Singapore for patients with hemorrhagic stroke. This session will describe the drug developmental history of CN-105 at Duke, the ongoing CATCH trial in the US through the DCRI, and the planned S-CATCH trial in Singapore through NNI and SCRI. Finally, the team will detail their experience in designing this trial and developing multisite collaboration in the US and Singapore for acute brain injury.